nexi-001 t cells
Cell therapyexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 29, 2020 (NCT04284228)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06572631 | Phase 1 | Dec 7, 2024 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT04505813 | Phase 1/Phase 2 (Phase 2) | Aug 17, 2020 | Advent Health, NexImmune Inc. |
| NCT04284228 | Phase 1/Phase 2 (Phase 2) | Feb 29, 2020 | NexImmune Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NexImmune Inc. | For profit | 2 | 2 | 1 | 2020 |
| Advent Health | Academic/Hospital | 1 | 0 | 1 | 2020 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2024 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2024 |
4 organizations
Page 1 / 1